Pharmaceutical companies take the wrong path: relying on practical research and development to counter attack the successful Yabang pharmaceutical industry

On November 16, the 80th anniversary of China Pharmaceutical University, Yabang pharmaceutical signed a contract with the university to build a joint research and Development Center for new pharmaceutical preparations It is reported that the R & D center planned to be built in the university will be supported by talents from China Medicine University and funds from Asian pharmaceutical industry "The construction of the joint R & D center is of great help to the subsequent completion of the generic consistency evaluation of Yabang pharmaceutical industry." Dr Chen Zaixin, President of Yabang Pharmaceutical Research Institute, said that at present, the research center has developed a series of long-term plans for consistency evaluation The low-key and implicit face-to-face consistency evaluation is the distinctive feature of Yabang pharmaceutical industry However, the scientific research strength and product quality of Yabang cannot be underestimated According to Ma Shaoming, general manager of Jiangsu Yabang Pharmaceutical Marketing Co., Ltd., there are two things in Yabang pharmaceutical industry, i.e., "at any cost", and new drug research and development is one of them Of course, this is also inseparable from the fact that the pharmaceutical industry of Yabang has a group of low-key and powerful outstanding scientific and technological workers For many years, Yabang pharmaceutical industry insists on scientific and technological innovation as the first productivity of the enterprise, and invests heavily in new products and technology development every year At present, Yabang Pharmaceutical Research Institute, as a key construction project of Changzhou City, has passed the acceptance successfully, and passed the acceptance with outstanding achievements in the implementation of Jiangsu enterprise R & D management system led by Jiangsu Provincial Department of science and technology Yabang Pharmaceutical Research Institute has three R & D platforms, including the technology platform for sustained-release and controlled-release preparations, the technology platform for chiral synthesis, and the R & D platform for new compound preparations, and has undertaken the construction of two technology platforms, i.e the Engineering Technology Research Center for new quinolones and the Engineering Technology Center for sustained-release and controlled-release preparations of Jiangsu Province (Yabang), which have been completed and accepted In 2012, Yabang pharmaceutical industry was approved to establish Jiangsu innovative drug Engineering Center for chronic lung disease By the end of September 2015, Yabang had established more than 70 new drug R & D projects and obtained more than 50 clinical approvals; the company has obtained 36 new drug approval numbers, including 5 first-class new drug certificates, 5 second-class new drugs and 26 third to sixth class new drugs; it has applied for 58 patents and authorized 28, including 1 utility model patent, 8 appearance patent and more than 20 invention patents At present, it has developed five series, 15 dosage forms and more than 200 specifications of high-tech special product groups covering anti infective drugs, cardio cerebrovascular drugs, respiratory system drugs, immune system drugs, fluid balance infusion and other fields Industry insiders commented that the continuous development of new drugs is conducive to improving the income structure of Yabang products and enhancing the profitability of enterprises in the pharmaceutical business in the future Compared with other large domestic pharmaceutical groups, the R & D team of Yabang pharmaceutical industry is more inclined to focus on practical technology, innovation of existing production technology, secondary R & D of generic drugs, etc This enables enterprises to get a solid foundation in the current wave of generic drug consistency evaluation "In the market, many generic drugs have problems such as weak basic and clinical research, lagging behind modern pharmaceutical technology, and lack of scientific evidence-based evidence for safety and effectiveness Therefore, it is imperative to evaluate the consistency of generic drugs." According to Chen Zaixin, the promotion of consistency evaluation encourages pharmaceutical enterprises to optimize and improve the process and quality standards of products with high safety, accurate efficacy and outstanding advantages, so as to make them bigger and stronger; However, those varieties whose prescriptions are not reasonable, whose curative effect is even, which have serious adverse reactions, and who do not take the initiative to re evaluate after being put on the market, can be eliminated and revoked Therefore, the consistency evaluation of generic drugs has the effect of eliminating "inferior" and "superior" According to Chen Zaixin, at present, Yabang pharmaceutical industry is actively passing the consistency evaluation on the advantageous varieties as soon as possible according to the future market situation of drugs, and constantly innovating and developing in all aspects of production and research and development This time, the joint research and development center of China Pharmaceutical University Changzhou Yabang pharmaceutical new pharmaceutical preparation Co., Ltd is expected to accelerate the promotion of enterprise consistency evaluation In the era of knowledge economy, pharmaceutical enterprises only rely on internal resources for high-cost R & D innovation, which has been difficult to adapt to the rapid development of market demand and increasingly fierce market competition "Open innovation R & D" is increasingly popular in the global mainstream market From the information center on the website of Yabang pharmaceutical industry, we can see the enterprise's attitude towards open innovation and R & D by listing the two contents of industry university research joint innovation and international cooperation separately Taking international integration as an example, through cooperation with foreign pharmaceutical enterprises in the development of innovative drugs, and using their own channels, experience and advantages to introduce technology into China, to obtain the rights and interests of China Pfizer's global R & D center in San Diego, gryhpon biotechnology company in the United States, live cell treatment center in Germany, icecure medical devices company in Israel, rainbow medical devices company in Israel The technical director of Yabang pharmaceutical industry frequently contacts and negotiates cooperation with overseas enterprises According to reports, the cooperation projects that have been implemented at present include the Chinese market agent of German stem cell therapy and Israel rainbow medical equipment company's cooperation on transvaginal minimally invasive hysteromyoma treatment technology and high-intensity focused ultrasound cooling treatment of benign prostatic hyperplasia technology The combination of industry, University and research, which takes technological innovation as the core, benefit sharing as the link and contractual relationship as the guarantee, can effectively extend the innovation ability of pharmaceutical enterprises Since 2010, Yabang Pharmaceutical Co., Ltd has reached cooperation with various colleges and Universities: establishing new drug R & D center of Nantong Yabang Pharmaceutical Co., Ltd with Nanjing University of technology, signing drug R & D cooperation agreement with Sichuan University to develop new anti superbug drugs, signing new anti-tumor drug technology cooperation agreement with Changzhou University, and co constructing Jiangnan health industry research with Nanjing University of traditional Chinese medicine and Wujin District People's government Research Institute and so on, as well as the joint research and development center of Changzhou Yabang pharmaceutical new drug preparation, which has just signed a contract to build At the same time, Yabang has established a long-term cooperative relationship with six experts of the national millennium plan "Whether it's the development of innovative drugs, the improvement of generic technology, or the evaluation of consistency, the intellectual support of colleges and universities can help enterprises a lot." Chen Zaixin frankly said that open innovation can make the academic circles that are good at exploratory innovation research better play their strengths and look for the latest solutions without restriction, while pharmaceutical enterprises focus on clinical development and application as well as academic promotion after listing "The technology of colleges and universities needs industrial transformation, and the strong cooperation between the two sides makes it easier to achieve win-win results."